Gonorrhea: Symptoms, Testing, Treatment, and Prevention

Gonorrhea (Neisseria gonorrhoeae) is the second most common bacterial STI in the U.S. Rising antibiotic resistance demands vigilant management.

Symptoms

MenWomen
Onset2–10 days7–14 days (often asymptomatic)
Urethral/CervicalDysuria, purulent discharge, meatal erythemaVaginal discharge, dysuria, intermenstrual bleeding
ComplicationsEpididymitis, prostatitisPID, tubal infertility, ectopic pregnancy, Fitz-Hugh-Curtis
ExtragenitalRectal (pain, discharge), pharyngeal (often asymptomatic)Same

Testing (NAAT Preferred)

  • Urine (first-catch), vaginal/endocervical swab, rectal/pharyngeal swabs per exposure sites.
  • Co-test for chlamydia (high co-infection rate).
  • Test-of-cure: pharyngeal gonorrhea (14 days); otherwise not routine if treated per guidelines.

Treatment (CDC 2021/2024 Updates)

  • Uncomplicated urogenital/rectal: Ceftriaxone 500 mg IM single dose (1 g if ≥150 kg).
  • Pharyngeal: Ceftriaxone 1 g IM.
  • Allergy: Gemifloxacin 320 mg + azithromycin 2 g PO (if cephalosporin allergy).
  • Partner Treatment: Expedited Partner Therapy (EPT) legal in most states.
  • Abstain 7 days after treatment and partner(s) treated.

Antimicrobial Resistance

Ciprofloxacin, azithromycin, penicillin, and tetracycline resistance is widespread. Ceftriaxone MIC creep is monitored (GISP). Dual therapy no longer routine (azithromycin dropped 2020).

Prevention

  • Condoms (external/internal) consistently.
  • Regular screening: sexually active women <25 annually; MSM at least annually (3–6 months if high risk).
  • PrEP users: quarterly STI screening.
  • Vaccination: HPV, Hep A/B (no gonorrhea vaccine yet).

Expedited partner treatment and prompt retesting at 3 months are critical to interrupt transmission.

Gonorrhea - Related Articles